We are looking for people with mild cognitive impairment (MCI) who are willing to take part in a large European study

AI-Mind study takes place in Norway, Finland, Italy and Spain, and it aims to involve 1’000 participants. 

The study will help to develop and validate artificial intelligence (AI) based tools to predict who is likely to develop dementia. 

Mild cognitive impairment (MCI)

MCI is a condition in which the person experiences some memory loss, problems with concentration and/or thinking but maintains the ability to independently perform most activities of daily living. These symptoms are greater than in normal ageing. MCI is not the same as dementia, some people with MCI may develop dementia but others can revert back to normal cognitive functioning or remain stable over time.

Artificial Intelligence (AI)

AI refers to the performance by computer programs of tasks that are commonly associated with intelligent beings. The use of AI systems is becoming more common in healthcare (e.g. to support diagnosis or make predictions, recommendations or decisions). AI-Mind will use AI to develop models that mimic the functionality of human brain to better understand the MCI and create tools to predict people’s risk of developing dementia.

Data protection

All the information collected from participants during the AI-Mind study will be kept confidential, securely encrypted and not used for purposes other than the AI-Mind project. 

Watch our video about the study

Are you taking care of your brain health?

 

Meet Mary. Mary is in her 60's and she works in administration.

 

Her doctor told her recently that she has a condition called Mild Cognitive Impairment.

 

This is not the same as dementia, but some people with this condition may have a higher risk of developing dementia in the future.

 

Doctors currently lack appropriate tools to better understand people’s likelihood of developing dementia at some point.

 

There is a new European research project called AI-Mind that could change this in the future. The aim of AI-Mind is to develop smart diagnostic tools to predict, at an early stage, who is likely to develop dementia.

 

The study will take place in Norway, Finland, Italy and Spain, and will involve a total of 1,000 participants.

 

Mary is quite interested in joining the AI-Mind study and supporting this important research.

 

By doing so, Mary would be helping ensure that AI-Mind develops effective diagnostic tools for people at risk of developing dementia across Europe.

 

If Mary decides to participate, she will be asked to attend four appointments over two years. That gives one appointment every 8 months.

 

Each appointment will last around two hours and will involve

 

a short interview,

an EEG test - a procedure to measure electrical activity in the brain and

cognitive tests about memory, thinking, language etc.

 

At the first meeting, Mary will also be asked for a blood sample to help the researchers better understand genetic factors linked to the risk of developing dementia.

 

But what if Mary changes her mind?

 

Well, that would be no problem. Participation in the study is voluntary and Mary can withdraw any time.

 

AI-Mind is looking for people aged between 60 and 75, who either have a diagnosis of Mild Cognitive Impairment or who are experiencing memory and concentration problems.

 

Would you like to find out more about this study?

 

If so, please contact the local study team.

Are you interested in joining the study?

You may be able to participate if you:

If your answer was “Yes” to all the above items and you want to join the study, please go to the local study page and contact the study team for your location.

Steps to follow

Go to the study page in your local language and contact the study team

Inform your doctor about the study and your interest in participation

Enroll in the AI-Mind study

Visit our clinical site 4 times over the next 2 years

What the visit would involve?

Interviews with the researchers

EEG and MEG tests (procedures to measure electrical activity in the brain)

Cognitive tests (tests of memory, thinking and language etc.)

A blood sample to understand genetic and other factors linked to the risk of developing dementia

Visit local study site

Norway, Oslo University Hospital

Dr. Ira Haraldsen

Italy, IRCCS San Raffaele Roma

Prof. Paolo Rossini

Italy, Università Cattolica del Sacro Cuore

Prof. Camillo Mara

Finland, Helsinki University Hospital 

Prof. Hanna Renvall

Spain, Complutense University of Madrid 

Prof. Fernando Maestú

Meet Sven, the study participant

I am 63 years old, have 2 children, I’m grandfather to 4 grandchildren, educated as an electrician and have worked in a technical team at Diakonhjemmet hospital for 6.5 years. 

I was worried about my memory and went to the GP with the problem. I even wanted a test to document if something was wrong. The diagnosis was made in 2015. 

What were the first signs that something had changed and what made you seek help?

Forgetfulness, messing with some things.

How long has this been going on?

Many years ago, before the diagnosis, I disappeared twice in different contexts. Once from an entourage in Turkey, where I came back at 02.00 at night. The second time, there was a similar happening at home.

Frequently asked questions (FAQ)

Clinical study is a type of research that involves volunteers (participants of the study) and aims to add knowledge to medical field. It may involve development of new treatments, drugs or preventive methods and aim to see what effect do they have on people. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. AI-Mind study is an observational study. 

You may find more  information on clinical studies here:

https://clinicaltrials.gov/ct2/about-studies/learn#ObservationalStudies

You may find more information about clinical trials here:

https://www.alzheimer-europe.org/Research/Understanding-dementia-research/Clinical-trials

The study will last around 2 years, involving 4 appointments every 8 months.

The visit will take around 2 hours, including tests and waiting time between. 

All the tests and procedures in the study are considered safe and none of them is invasive, except for the blood sample at the first visit. There are no known or anticipated risks to you if you join the study. 

No, the study does not involve the development of a medicine and therefore you will not be asked to take an investigational drug.

You do not have to pay for the study. We will cover all costs for medical investigations. However, reimbursement of the travel costs depends on the local study site. Please visit local study pages for more information. 

You do not have to be diagnosed with MCI to participate in the study. Please contact our study team if you have observed problems in memory or other cognitive decline and wish to participate.

Participation in the study is voluntary, you can withdraw at any time.

Your safety as a participant as well as of our study team is our highest priority. You can be confident that you will receive safe, high-quality, compassionate care from the extraordinary health care teams at any of our study locations. Please feel free to contact our local study team for more information.

AI-Mind study has been approved by the National Committees for Medical and Health Research Ethics and we put every effort to ensure that you’re comfortable with your participation. However, if you have any concerns or complaints about the study, please feel free to contact project coordinator at: contact@ai-mind.eu